MiMedx Group, Inc. to Present at the 10th Annual Needham Healthcare Conference

MARIETTA, Ga., March 16, 2011 /PRNewswire/ -- MiMedx Group, Inc. (OTC Bulletin Board: MDXG), an integrated developer, manufacturer and marketer of patent protected biomaterial-based products, announced today that it will present at the 10th Annual Needham Healthcare Conference in New York.  Parker H. "Pete" Petit, Chairman and CEO, William C. Taylor, President and COO of MiMedx, and John Daniel, President of Surgical Biologics, a wholly-owned subsidiary of MiMedx, are scheduled to present on Wednesday, April 6th, at 10:00 a.m. Eastern Time at the New York Palace Hotel in New York City.  A webcast of this presentation will be available on the Company's website, www.mimedx.com.  

About the Company

MiMedx is an integrated developer, manufacturer and marketer of patent protected biomaterial-based products and bioimplants manufactured from human amniotic membrane. The Company is successfully emerging from a development-focused start-up into a fully integrated operating company with an experienced team poised to capitalize on its science and technology to generate rapid sales growth and profitability.  Our mantra is "Repair, don't replace" because our biochemists, engineers, designers and physicians believe it is better to augment repair when possible rather than replace traumatized, but otherwise healthy tissues and structures.  Our platform technologies, HydroFix™ and CollaFix™, and our newest platform technology, Purion® developed by our wholly-owned subsidiary, Surgical Biologics, have a vast number of potential applications in treating traumatized tissue and structures and MiMedx is focused on commercializing multiple applications for the Company's three technology platforms. In parallel, we are seeking strategic relationships, in selective categories, to more rapidly commercialize our technologies.  

SOURCE MiMedx Group, Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED